Final analysis of the MINT study demonstrates durable outcomes for mogamulizumab in patients with mycosis fungoides (MF) and Sézary syndrome (SS). This real-world evidence supports the drug's efficacy in treating these rare skin lymphomas.

The FIL-MOGA study highlights sustained response (ORR4) as a prognostic marker for patients with mycosis fungoides and Sézary syndrome treated with mogamulizumab. This research could influence treatment strategies for these rare skin lymphomas.

Recent research highlights oral mycosis fungoides, a rare form of cutaneous T-cell lymphoma affecting the oral cavity. This study contributes to the understanding of its clinical presentation and management.

A recent study highlights the psychological distress and symptom burden faced by patients with mycosis fungoides and Sézary syndrome, impacting their overall quality of life. This research underscores the need for comprehensive care strategies addressing both physical and mental health in these patients.